SCHEMBL10075701

SCHEMBL10075701

CCC1=CC=NC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13063118 0.75
SCHEMBL22845097 0.70 NOS3 (0.31)
SCHEMBL824741 0.63
SCHEMBL18525736 0.63
SCHEMBL12817035 0.61
SCHEMBL27629444 0.59
SCHEMBL14619476 0.56
SCHEMBL1628933 0.54
SCHEMBL1097724 0.54
SCHEMBL22642160 0.54 NOS3 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023282702-A1 SHP2 INHIBITOR AND USE THEREOF 주식회사 카나프테라퓨틱스 2023-01-12 WO disclosed
EP-2970303-B3 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES INC (US) 2018-08-01 EP disclosed
US-10005774-B2 Syk inhibitors GILEAD SCIENCES, INC. (US) 2018-06-26 US disclosed
EP-3002283-B1 THIAZOLE DERIVATIVES KYOWA HAKKO KIRIN CO LTD (JP) 2017-06-14 EP disclosed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 US disclosed
US-9376441-B2 Substituted pyrrolidines as SYK inhibitors GILEAD SCIENCES, INC. (US) 2016-06-28 US disclosed
US-9365545-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC (US) 2016-06-14 US disclosed
WO-2016053289-A1 TOPICAL COMPOSITIONS AND METHODS FOR SKIN LIGHTENING AVON PRODUCTS, INC. (US) 2016-04-07 WO disclosed
US-20150336931-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC 2015-11-26 US disclosed
CN-104902749-A Method for promoting plant growth SUMITOMO CHEMICAL CO 2015-09-09 CN disclosed
US-9108921-B2 Therapeutic compounds and compositions AGIOS PHARMACEUTICALS, INC (US) 2015-08-18 US disclosed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 US disclosed
WO-2014164200-A1 TYROSINASE INHIBITORS AVON PRODUCTS, INC (US) 2014-10-09 WO disclosed
US-20140288081-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC (US) 2014-09-25 US disclosed
US-8394427-B2 Paxillin stimulating compositions and cosmetic uses thereof AVON PRODUCTS, INC. (US) 2013-03-12 US disclosed
US-20120328546-A1 Paxillin Stimulating Compositions and Cosmetic Uses Thereof AVON PRODUCTS, INC. (US) 2012-12-27 US disclosed
US-8168212-B2 Topical compositions comprising non-proteogenic amino acids and methods of treating skin AVON PRODUCTS, INC (US) 2012-05-01 US disclosed
US-20110151029-A1 Paxillin Stimulating Compositions and Cosmetic Uses Thereof AVON PRODUCTS, INC. (US) 2011-06-23 US disclosed
US-20100261769-A1 Topical Compositions Comprising Non-Proteogenic Amino Acids and Methods of Treating Skin AVON PRODUCTS, INC. (US) 2010-10-14 US disclosed
CN-1091288-A The oxytocin antagonist OTSUKA PHARMA CO LTD (JP) 1994-08-31 CN disclosed